GSBR-1290, a selective oral GLP-1 receptor agonist that targets obesity and type 2 diabetes, has undergone Phase 2a trials, and results are to be released by the firm very soon. Meanwhile, the ...
About ALKS 2680 ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a ...
Skye provides webcast link for corporate presentationSAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SKYE) (“Skye”), a ...
MONDAY, June 3, 2024 (HealthDay News) -- Ozempic and Wegovy might help lower the risk of pancreatitis in patients with ...
Thinking about using a GLP-1 agonist like Ozempic, Mounjaro, or Wegovy? Here are four ways to simulate the effects naturally ...
Women taking the medication after 16 weeks better sensed lower concentrations of flavors and had notable changes in brain ...
FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or ...
Apalutamide plus androgen deprivation therapy does not appear to negatively impact quality of life in patients with recurrent ...
Seeking Alpha analysts weigh in on which stocks investors should be watching in the lucrative weight-loss drug space besides ...
Wegovy is the FDA approved GLP-1 agonist that is specifically approved to treat obesity. These drugs have clear benefits and ...
Medpage Today on MSN1d
Novel CD40 Agonist-Chemo Combo Shows Promise in Pancreatic CancerC HICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in ...
Efti in combination with KEYTRUDA with or without chemotherapy has generated compelling efficacy and favourable safety in 1L NSCLC, one of the most relevant cancer indications with a high unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback